10 Lymphoma Clinical Trials in Minneapolis, MN (2026)

Q: How do I join a clinical trial in Minneapolis?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Minneapolis research site will contact you.

Recruiting Lymphoma Studies in Minneapolis

NCT05006482Recruiting

Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial

This phase III trial compares the effect of geriatric evaluation and management with survivorship health education (GEM-S) to usual care on patient-reported physical function in older survivors of can...

Minneapolis, MNPHASE3668 participantsUniversity of Rochester

View Study Details

NCT03922724Recruiting

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Background: Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause. Objective:...

Minneapolis, MNPHASE2330 participantsNational Cancer Institute (NCI)

View Study Details

NCT05512390Recruiting

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma....

Minneapolis, MNPHASE1154 participantsAbbVie

View Study Details

NCT03125642Recruiting

Auto Stem Cell Transplant for Lymphoma Patients

This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive....

Minneapolis, MNPHASE2150 participantsMasonic Cancer Center, University of Minnesota

View Study Details

NCT03666000Recruiting

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T,...

Minneapolis, MNPHASE1135 participantsImugene Limited

View Study Details

NCT06792825Recruiting

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

The study follows a Simon's two-stage phase II trial design to evaluate the safety and efficacy of tafasitamab added to rituximab and lenalidomide for two treatment-naïve, parallel, independent cohort...

Minneapolis, MNPHASE265 participantsMasonic Cancer Center, University of Minnesota

View Study Details

NCT03681561Recruiting

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose...

Minneapolis, MNPHASE154 participantsVeronika Bachanova

View Study Details

NCT04626791Recruiting

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

This phase II trial investigates how well modified VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride) and acalabrutinib as first line...

Minneapolis, MNPHASE245 participantsAcademic and Community Cancer Research United

View Study Details

NCT06536049Recruiting

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

This phase Ib/II trial evaluates the safety, optimal dose, and efficacy of the combination of epcoritamab and ibrutinib in treating patients with aggressive B-cell non-Hodgkin lymphoma that has come b...

Minneapolis, MNPHASE138 participantsYazeed Sawalha

View Study Details

NCT05370430Recruiting

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)...

Minneapolis, MNPHASE136 participantsPeproMene Bio, Inc.

View Study Details

About Lymphoma Clinical Trials in Minneapolis

Lymphoma is a cancer of the lymphatic system that affects infection-fighting cells called lymphocytes. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma. Treatment often includes chemotherapy, radiation, immunotherapy, and in some cases stem cell transplant.

There are currently 10 lymphoma clinical trials recruiting participants in Minneapolis, MN. These studies are seeking a combined 1,675 participants. Research is being sponsored by University of Rochester, National Cancer Institute (NCI), AbbVie and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lymphoma Clinical Trials in Minneapolis — FAQ

Are there lymphoma clinical trials in Minneapolis?

Yes, there are 10 lymphoma clinical trials currently recruiting in Minneapolis, MN. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Minneapolis?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Minneapolis research site will contact you about next steps.

Are clinical trials in Minneapolis free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Minneapolis studies also compensate for your time and travel.

What lymphoma treatments are being tested?

The 10 active trials in Minneapolis are testing new therapies including novel drugs, biologics, and treatment approaches for lymphoma.

Data updated July 19, 2026 from ClinicalTrials.gov